Theravance Biopharma, Inc.
corporate_fare Company Profile
Theravance Biopharma, Inc. (NASDAQ:TBPH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for TBPH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-18, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 14 rated 8 or above. Recent SEC coverage for TBPH spans 8-K, DEFA14A, DEFM14A, PREM14A.
Recent high-impact activity:
- Theravance Shareholders Approve $17/Share Zymeworks Merger; Closing Expected Sept 23
- Lawsuits Seek to Block Theravance's $17/Share Sale to Zymeworks
- Theravance Discloses Three Merger Lawsuits and Supplemental Proxy Details Ahead of Sept 18 Vote
- Theravance Discloses CYPRESS Phase 3 Miss and FDA Path Forward for Ampreloxetine
- CYPRESS Phase 3 Misses Primary Endpoint, but FDA Signals Path Forward for Ampreloxetine
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$107.46M
Net Income
$105.89M
Diluted EPS
$2.06
Op. Cash Flow
$238.54M
Free Cash Flow
$238.5M
Operating Income
-$3.6M
Cash & Equivalents
$167.81M
Debt / Equity
0.00×
Net Margin
98.5%
Shares Outstanding
51.07M sh
Source: 10-K · filed 2026-03-23 · accession 0001104659-26-033077
feed TBPH - Latest Insights
TBPH
Sep 18, 2026, 5:16 PM EDT
TBPH
Sep 10, 2026, 11:03 AM EDT
TBPH
Sep 10, 2026, 9:10 AM EDT
TBPH
Aug 25, 2026, 4:54 PM EDT
TBPH
Aug 25, 2026, 4:52 PM EDT
TBPH
Aug 21, 2026, 6:27 AM EDT
TBPH
Aug 11, 2026, 8:13 AM EDT
TBPH
Aug 10, 2026, 8:35 AM EDT
TBPH
Aug 10, 2026, 8:30 AM EDT
TBPH
Jul 01, 2026, 7:33 PM EDT
TBPH
Jun 29, 2026, 6:32 AM EDT
TBPH
Jun 29, 2026, 6:30 AM EDT
TBPH
Jun 29, 2026, 6:00 AM EDT
TBPH
May 07, 2026, 9:00 AM EDT
TBPH
May 07, 2026, 8:36 AM EDT
TBPH
May 07, 2026, 8:33 AM EDT
TBPH
Apr 28, 2026, 4:59 PM EDT
TBPH
Mar 23, 2026, 8:46 AM EDT
TBPH
Mar 19, 2026, 8:38 AM EDT
TBPH
Mar 03, 2026, 8:46 AM EST